DE69920031D1 - Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose - Google Patents

Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose

Info

Publication number
DE69920031D1
DE69920031D1 DE69920031T DE69920031T DE69920031D1 DE 69920031 D1 DE69920031 D1 DE 69920031D1 DE 69920031 T DE69920031 T DE 69920031T DE 69920031 T DE69920031 T DE 69920031T DE 69920031 D1 DE69920031 D1 DE 69920031D1
Authority
DE
Germany
Prior art keywords
vegf
genes
proteins
prevent restenosis
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920031T
Other languages
English (en)
Other versions
DE69920031T2 (de
Inventor
Seppo Yla-Herttuala
Kari Alitalo
O Hiltunen
Markku M Jeltsch
G Achen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vegenics Pty Ltd
Original Assignee
Licentia Oy
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Oy, Ludwig Institute for Cancer Research New York filed Critical Licentia Oy
Application granted granted Critical
Publication of DE69920031D1 publication Critical patent/DE69920031D1/de
Publication of DE69920031T2 publication Critical patent/DE69920031T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69920031T 1998-10-26 1999-10-26 Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose Expired - Lifetime DE69920031T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
US105587P 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (2)

Publication Number Publication Date
DE69920031D1 true DE69920031D1 (de) 2004-10-14
DE69920031T2 DE69920031T2 (de) 2005-09-22

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920031T Expired - Lifetime DE69920031T2 (de) 1998-10-26 1999-10-26 Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (de)
JP (2) JP4769929B2 (de)
CN (1) CN1338943A (de)
AT (1) ATE275417T1 (de)
AU (1) AU768330B2 (de)
CA (1) CA2340593C (de)
DE (1) DE69920031T2 (de)
ES (1) ES2229788T3 (de)
NO (1) NO20012017L (de)
NZ (1) NZ510121A (de)
PT (1) PT1126870E (de)
WO (1) WO2000024412A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2400948A1 (en) 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
WO2001091803A2 (en) * 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
MXPA03006315A (es) * 2001-01-16 2004-12-03 Vascular Therapies Llc Dispositivo que se puede implantar y que contiene un material matriz que se puede reabsorber y medicamentos antiproliferativos para prevenir o tratar fallas de acceso vascular por hemodialisis y de otros injertos vasculares.
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
WO2003092727A1 (en) * 2002-04-30 2003-11-13 Fit Biotech Oyj Plc Medical device
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
JPWO2005039556A1 (ja) * 2003-10-29 2007-02-15 紘一 首藤 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
US20070077266A1 (en) * 2004-03-18 2007-04-05 Kensuke Egashira Drug/gene eluting stent
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
CA2663547C (en) 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
ES2251740T3 (es) * 1996-08-23 2006-05-01 Ludwig Institute For Cancer Research Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
CA2287538A1 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Also Published As

Publication number Publication date
CA2340593A1 (en) 2000-05-04
DE69920031T2 (de) 2005-09-22
JP2002528420A (ja) 2002-09-03
AU768330B2 (en) 2003-12-11
JP2011173874A (ja) 2011-09-08
WO2000024412A3 (en) 2000-08-03
AU1314700A (en) 2000-05-15
NZ510121A (en) 2003-02-28
WO2000024412A2 (en) 2000-05-04
JP5231587B2 (ja) 2013-07-10
ES2229788T3 (es) 2005-04-16
CA2340593C (en) 2012-05-08
CN1338943A (zh) 2002-03-06
EP1126870B1 (de) 2004-09-08
PT1126870E (pt) 2005-01-31
JP4769929B2 (ja) 2011-09-07
EP1126870A2 (de) 2001-08-29
NO20012017D0 (no) 2001-04-24
ATE275417T1 (de) 2004-09-15
NO20012017L (no) 2001-06-26

Similar Documents

Publication Publication Date Title
DE69920031D1 (de) Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69433478D1 (de) Verwendung von stickoxid-addukten zur verhütung von thrombosen auf artifiziellen und vaskulären oberflächen
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
DE69839060D1 (de) Vegi, ein inhibitor der angiogenese und des tumorwachstums
ATE271882T1 (de) Supplementierte verdichtungsmittel für gewebe, methoden für ihre herstellung und ihre verwendung
ATE288424T1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE277034T1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE86869T1 (de) Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
DK1113810T3 (da) Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
DE69841041D1 (de) Stent beschichtet mit dna
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE68913991D1 (de) Implantat zur verwendung in der knochenchirurgie.
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
DE69022776D1 (de) Verwendung von keramischen Materialen als Ersatzmaterialien für lebendes Gewebe.
DE59712847D1 (de) Monoklonaler Antikörper gegen MxA und MxB
ATE228371T1 (de) Verwendung von cd137 zur förderung der proliferation peripherer monocyten
ATE222501T1 (de) Tissue-faktor zur beeinflussung von gefässbildung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: VEGENICS LTD., TOORAK, VICTORIA, AU